Roivant Splashes Cash Again To License GSK Skin Disorder Drug
Executive Summary
The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof to Dermavant, banking a hefty £150m up front and possibly another £100m after that.
You may also be interested in...
Dermavant's Tapinarof Could Bring Innovation To Topical Psoriasis Market
CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.
Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.
Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.